Tom G. Sheidow

Tom G. Sheidow

Auto-generated profile, based on publicly available information

Tom G. Sheidow

Vitreoretinal Surgeon, Ivey Eye Institute, St Joseph's Hospital, London, ON, Canada; Associate Professor, Ophthalmology, Western University, London, ON, Canada

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2003 in Ophthalmology
Verified
Journal Article
Closed access
TSTom G Sheidow
Tom G Sheidow
KBKevin J Blinder
Kevin J Blinder
NHNancy Holekamp
Nancy Holekamp
DJDaniel Joseph
Daniel Joseph
GSGaurav Shah
Gaurav Shah
SSSanjay Sharma
Sanjay Sharma

13 July 2013 in British Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
FHFrank G Holz
Frank G Holz
Francesco BandelloFrancesco Bandello
Francesco Bandello
MGMark Gillies
Mark Gillies
PMPaul Mitchell
Paul Mitchell
AOAaron Osborne
Aaron Osborne
OCon behalf of the LUMINOUS Steering Committee
on behalf of the LUMINOUS Steering Committee
Purpose Evaluation of 1-year safety profile of intravitreal ranibizumab 0.5 mg in neovascular age-related macular degeneration (NV-AMD) within routine clinical practice. Methods The LUMINOUS programme comprises a prospective observational study assessing ranibizumab ‘real-world’ safety and clinical effectiveness across licensed indications worldwide and an annual retrospective pooled safety analysis from completed NV-AMD ranibizumab registries. 1-year data from four European registries are available. This retrospective pooled safety analysis assessed 1-year incidence rates for safety events of particular interest (key ocular or systemic events possibly related to the injection procedure or vascular endothelial growth factor inhibition) together with treatment exposure. Patients were treated according to local protocols within the ranibizumab licence. Results Data of 4444 patients from registries in Germany (n=3470), the Netherlands (n=243), Belgium (n=260) and Sweden (n=471) were retrospectively pooled. Between 70.4% and 84.4% of enrolled patients completed 1 year of follow-up. Most frequent overall ocular events of particular interest were retinal pigment epithelial tears (27 patients; <1%) and intraocular pressure-related events (12 patients; <0.3%). Most frequent non-ocular event of particular interest was stroke (19 patients; 0.4%); annual incidence of stroke was low across all registries (0.0–0.5%). Conclusions Ranibizumab demonstrated favourable 1-year safety profile for NV-AMD in this routine clinical practice sample, consistent with previous reported trial data. Additional data from a larger patient population are needed to better describe the long-term safety profile of ranibizumab in routine clinical practice and further evaluate risk for infrequent but serious events in ‘real-life’ settings. The 5-year LUMINOUS prospective observational study will address this need.

1 June 2019 in Ophthalmology
Verified
Journal Article
Open access
PKPeter J. Kertes
Peter J. Kertes
IGIvan J. Galic
Ivan J. Galic
MGMark Greve
Mark Greve
RWR. Geoff Williams
R. Geoff Williams
EREmmanouil Rampakakis
Emmanouil Rampakakis
TSTom Sheidow
Tom Sheidow
To compare the efficacy of ranibizumab using a treat-and-extend (T&E) regimen with monthly dosing in treatment-naive patients with neovascular age-related macular degeneration (nAMD). Prospective, randomized, open-label, multicenter, noninferiority, postauthorization study. Treatment-naive patients with choroidal neovascularization secondary to AMD. Patients with nAMD were randomized 1:1 to receive intravitreal ranibizumab at a dose of 0.5 mg in either a T&E or monthly dosing regimen. The noninferiority of T&E compared with the monthly dosing regimen was to be shown using a margin of 5 letters in best-corrected visual acuity (BCVA) improvement. Mean change in BCVA in Early Treatment Diabetic Retinopathy Study letters from baseline to month 12. Baseline and 12-month visual acuity data are available for 526 patients (T&E, n = 268; monthly, n = 258). At baseline, mean age was 78.8 years (standard deviation [SD], 7.8 years), 60.3% were women, and 94.3% were white. No significant between-group baseline differences were observed. The primary outcome of noninferiority regarding visual acuity was met with mean BCVA improvement of 8.4 letters (SD, 11.9 letters) and 6.0 letters (SD, 11.9 letters; P = 0.017) in the T&E and monthly regimens, respectively, with a between-group mean difference of 2.38 letters (95% confidence interval, 0.32-4.45 letters). Per protocol, a secondary analysis was performed to test for superiority of number of injections received up to month 12. This analysis demonstrated significantly fewer injections with T&E versus monthly dosing (9.4 and 11.8 injections, respectively), with a mean difference of -2.46 injections (95% confidence interval, -2.68 to -2.23 injections). The 12-month results of this 2-year study demonstrated that regarding visual outcomes, the T&E regimen was noninferior to a monthly dosing regimen. Similar visual outcomes in the T&E group as in the monthly dosing group were achieved with significantly fewer injections.

21 November 2010 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
JRJohane M Robitaille
Johane M Robitaille
BZBinyou Zheng
Binyou Zheng
KWKarin Wallace
Karin Wallace
MBM Jill Beis
M Jill Beis
CTCuneyt Tatlidil
Cuneyt Tatlidil
DGDuane L Guernsey
Duane L Guernsey
Aim The aim of this study is to assess the role of Frizzled-4 (FZD4) in familial exudative vitreoretinopathy (FEVR) and Coats disease. Methods Tissue samples were collected for DNA extraction and automated DNA sequencing of the two coding exons of FZD4 in both directions. Cases carrying a FZD4 mutation and demonstrating extreme disease severity were selected for direct automated sequencing of all coding exons of LRP5, NDP and TSPAN12. Clinical data were obtained for the purpose of identifying genotype–phenotype correlations. Results 68 probands were diagnosed as having autosomal dominant or sporadic FEVR. Eleven FZD4 mutations (five missense, three deletions, one insertion, two nonsense) were identified. Six of these mutations are novel, and none were found in 346 control chromosomes. In 16 cases of Coats disease, one polymorphism combination was found in two samples: no mutations were detected. No genotype–phenotype correlation emerged. Three severely affected cases with FZD4 mutations failed to show additional mutations in the three other FEVR genes. Conclusion The authors identified 12 FEVR probands with FZD4 mutations. FZD4 mutation screening can be a useful tool especially in mild or atypical cases of FEVR. Germ-line mutations in FZD4 do not appear to be a common cause of Coats disease.

1 July 2000 in British Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
TST. G Sheidow
T. G Sheidow
AIMS To evaluate the expression of vascular endothelial growth factor (VEGF) in uveal melanomas and correlate its presence with tumour characteristics and systemic metastasis. METHODS 47 cases of ciliochoroidal melanoma enucleated between 1983 and 1993 were retrieved from the pathology archives at the University of Western Ontario. Paraffin sections stained with haematoxylin and eosin, periodic acid Schiff, and periodic acid Schiff without haematoxylin after bleaching of melanin were examined. The expression of VEGF protein was examined by an immunoalkaline phosphatase method following antigen retrieval, using an antibody to VEGF and vector red as the chromogen. The intensity of VEGF immunoreactivity was graded on a scale of 0–7 and correlated with tumour cell type, tumour size, presence or absence of necrosis, pigmentation, mitotic activity, microvascular density, and microvascular pattern. RESULTS VEGF immunoreactivity was present in 44/47 tumours (94%): the intensity was graded as very weak (1–2) in 29/47 (62%) and as weak or greater in 15/47 (32%). VEGF was also found in the ciliary epithelium, smooth muscle of the ciliary body and iris, retinal ganglion cells, inner photoreceptor segments, and the retinal pigment epithelium. Follow up data were available in 43/47 patients (91.5%), with a median follow up time of 10 years. 16/43 (37%) patients developed metastases. VEGF expression in melanoma was linked to the presence of tumour necrosis and the degree of pigmentation but no statistically significant relation with microvascular pattern, tumour size, or microvascular density was found. There was no statistically significant correlation between VEGF expression and metastasis. CONCLUSIONS Most ciliochoroidal melanomas express VEGF and expression is correlated with the presence of necrosis but not with the occurrence of systemic metastasis or tumour angiogenesis.

1 July 2000 in Eye
Verified
Journal Article
Closed access
TSTom G Sheidow
Tom G Sheidow
DNDavid A Nicolle
David A Nicolle
JHJ Godfrey Heathcote
J Godfrey Heathcote